HUMA241220P5000
- 1.05
- -0.10-8.70%
Humacyte Newsroom
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
Promising Clinical Outcomes and Imminent FDA Approval Bolster Buy Rating for Humacyte's Bioengineered Vessel
Humacyte Is Maintained at Buy by D. Boral Capital
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $12
Humacyte Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Humacyte Analyst Ratings
Piper Sandler Maintains Humacyte(HUMA.US) With Hold Rating, Maintains Target Price $6
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $12
Humacyte Is Maintained at Buy by D. Boral Capital
Humacyte Price Target Maintained With a $25.00/Share by D. Boral Capital
Humacyte Analyst Ratings
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $15
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
Buy Rating Affirmed for Humacyte Amid Promising Regulatory Outlook and Solid Financial Position
Humacyte Analyst Ratings
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $12
Humacyte's ATEV: Promising Clinical Performance and Market Potential Drive Buy Rating
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
Humacyte Price Target Maintained With a $25.00/Share by EF Hutton